276 related articles for article (PubMed ID: 20607352)
1. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
[TBL] [Abstract][Full Text] [Related]
2. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
Trinkaus M; Vranic A; Dolenc VV; Lah TT
Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
[TBL] [Abstract][Full Text] [Related]
6. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
[TBL] [Abstract][Full Text] [Related]
7. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
Ongaratti BR; Silva CB; Trott G; Haag T; Leães CG; Ferreira NP; Oliveira MC; Pereira-Lima JF
Braz J Med Biol Res; 2016; 49(4):e5125. PubMed ID: 27007654
[TBL] [Abstract][Full Text] [Related]
8. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.
Ke HL; Ke RH; Li ST; Li B; Lu HT; Wang XQ
J Neurooncol; 2013 Jun; 113(2):327-32. PubMed ID: 23525949
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
11. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.
Aarhus M; Bruland O; Bredholt G; Lybaek H; Husebye ES; Krossnes BK; Vedeler C; Wester K; Lund-Johansen M; Knappskog PM
J Neurooncol; 2008 Jul; 88(3):251-9. PubMed ID: 18365142
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
[TBL] [Abstract][Full Text] [Related]
15. P53 overexpression and proliferative potential in malignant meningiomas.
Nagashima G; Aoyagi M; Yamamoto M; Yamamoto S; Wakimoto H; Ohno K; Yamamoto K; Hirakawa K
Acta Neurochir (Wien); 1999; 141(1):53-61; discussion 60-1. PubMed ID: 10071687
[TBL] [Abstract][Full Text] [Related]
16. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
17. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
18. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
20. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
